[Selection of postoperative adjuvant therapy for patients with stage IB lung adenocarcinoma: analysis of 653 cases].
Nan Fang Yi Ke Da Xue Xue Bao
; 44(5): 989-997, 2024 May 20.
Article
in Zh
| MEDLINE
| ID: mdl-38862458
ABSTRACT
OBJECTIVE:
To explore the optimal postoperative adjuvant regimens for patients with stage IB lung adenocarcinoma.METHODS:
We respectively analyzed the data of 653 patients undergoing surgery for stage IB lung adenocarcinoma in our hospital from January, 2013 to December, 2021. The 5-year disease-free survival (DFS) and overall survival (OS) rates were compared among the patients receiving postoperative adjuvant therapy with epidermal growth factor-tyrosine kinase inhibitors (EGFR-TKIs group, n=111), chemotherapy (CT group, n=108) and clinical observation (CO group, n=434).RESULTS:
In TKIs, CT, and CO groups, the 5-year DFS rates were 92.8%, 80.7%, and 81.7%, respectively, significantly higher in TKIs group than in CO group (P < 0.01). The 3-year OS rates of the 3 groups were 96.8%, 97.1%, and 91.7%, respectively. Subgroup analysis showed that in TKIs, CT, and CO groups, the 5-year DFS rates of patients with with T3-4 cmN0M0 were 92.6%, 84.0%, and 81.4%, respectively, significantly higher in TKIs group than in CO group (P < 0.05); the 5-year DFS rates of T2ViscPlN0M0 patients were 95.1%, 71.4%, and 83.5%, respectively. Multivariate COX regression analysis showed that age (P < 0.05; HR=0.631, 95% CI 0.401-0.993), solid nodules (P < 0.01; HR=7.620, 95% CI 3.037-19.121), micropapillary or solid component (P < 0.05; HR= 1.776, 95% CI 1.010-3.122), lymphovascular invasion (P < 0.05; HR=2.981, 95% CI 1.198-7.419), and adjuvant therapy (P < 0.01) were independent predictors of DFS. The most common adverse effects included rashes, paronychia, and diarrhea for TKIs and hematological suppression and gastrointestinal reactions for chemotherapy, and TKIs were associated with a higher incidence of grade 3 or above adverse effects (44.4% vs 9.0%).CONCLUSION:
Adjuvant therapy with TKIs helps improve DFS in patients with stage IB (T3-4cmN0M0) lung adenocarcinoma but not in patients with T2ViscPlN0M0. Adjuvant chemotherapy does not improve DFS or OS in patients with stage IB lung adenocarcinoma.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Adenocarcinoma of Lung
/
Lung Neoplasms
/
Neoplasm Staging
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
Zh
Journal:
Nan Fang Yi Ke Da Xue Xue Bao
Year:
2024
Document type:
Article
Affiliation country: